The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Multiple Myeloma
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
-
Rocky Mountain Cancer Centers, Aurora, Colorado, United States, 80012-5405
Mayo Clinic Florida, Jacksonville, Florida, United States, 32224
Tampa General Hospital, Tampa, Florida, United States, 33606
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States, 33612-9416
Cleveland Clinic, Weston, Florida, United States, 33331-3609
University Cancer Blood Ctr, Athens, Georgia, United States, 30607-1465
The Winship Cancer Institute of Emory University, Atlanta, Georgia, United States, 30322-1013
Augusta University - Georgia Cancer Center, Augusta, Georgia, United States, 30912
The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago, Illinois, United States, 60637-1426
University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion, Westwood, Kansas, United States, 66205-2003
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2036-01-01